e-therapeutics is integrating computational power and biology to accelerate the discovery of life-transforming RNAi medicines.
We have developed and validated a powerful computational approach to drug discovery, leveraging our industry-leading expertise in network biology to fully capture and interrogate human disease complexity. Our multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support.
Our biology-led in silico laboratory enables rapid hypothesis generation, phenotypic screening and the identification and prioritisation of novel therapeutic targets. We have developed a proprietary GalNAc-siRNA platform technology for highly specific silencing of gene expression in the liver. Harnessing internal target gene discoveries, we are building an in-house pipeline of next-generation RNAi-based medicines.
e-therapeutics is listed on the Alternative Investment Market of the London Stock Exchange (“AIM”), with ticker symbol ETX. e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States (US), under the ticker symbol ETXPF.
Number of AIM securities in issue: 514,571,069 ordinary shares of 0.1p
Percentage of AIM securities not in public hands: 38.1%
There are no restrictions on the transfer of the Company’s ordinary shares.
Last updated: 13 January 2022.
- Richard Griffiths and controlled undertakings – 143,539,105 (27.89%)
- Robert Quested - 68,320,000 (13.28%)
- Ali Mortazavi – 50,941,666 (9.90%)
- M&G – 34,375,000 (6.68%)
- Trillian Ltd – 30,454,847 (5.92%)
- David Richardson - 24,779,030 (4.82%)
- Lombard Odier Asset Management – 18,082,221 (3.51%)
Last updated: 21 February 2022.
Nominated advisor and broker
SP Angel Corporate Finance LLP
Prince Frederick House
35–39 Maddox Street
020 3470 0470
Bank of Scotland
PO Box No 10
38 St. Andrew Square
Tel: +44 (0) 131 465 3900
Neville Registrars Limited
18 Laurel Lane
Tel: +44 (0) 121 585 1131
Fax: +44 (0) 121 585 1132
Grant Thornton UK LLP
30 Finsbury Square
Stephenson Harwood LLP
1 Finsbury Circus
Tel: +44 (0) 20 7329 4422
Upcoming meetings and events throughout the financial year.
|Preliminary Results||04 May 2022|
|AGM||19 July 2022|